Literature DB >> 12975103

[Genetics and quaternary prevention. The example of haemochromatosis].

J Gérvas1, M Pérez Fernández.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12975103      PMCID： PMC7681808          DOI： 10.1016/s0212-6567(03)79238-5

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  15 in total

1.  Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled.

Authors:  J E Haddow; L A Bradley
Journal:  BMJ       Date:  1999-08-28

2.  Will genetics revolutionize medicine?

Authors:  N A Holtzman; T M Marteau
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

3.  [Cascade effect: clinical, epidemiological and ethical implications].

Authors:  Mercedes Pérez-Fernández; Juan Gérvas
Journal:  Med Clin (Barc)       Date:  2002-01-26       Impact factor: 1.725

4.  Genetics and medicalisation.

Authors:  David Melzer; Ron Zimmern
Journal:  BMJ       Date:  2002-04-13

Review 5.  [Hyperlipidemia and primary prevention of ischemic heart disease].

Authors:  J Gérvas; M Pérez Fernández
Journal:  Med Clin (Barc)       Date:  1997-10-25       Impact factor: 1.725

6.  Haemochromatosis gene C282Y homozygotes in an elderly male population.

Authors:  G Willis; J Z Wimperis; K C Smith; I W Fellows; B A Jennings
Journal:  Lancet       Date:  1999-07-17       Impact factor: 79.321

7.  Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload.

Authors:  C Anne McCune; Layla N Al-Jader; Alison May; Sara L Hayes; Helen A Jackson; Mark Worwood
Journal:  Hum Genet       Date:  2002-09-26       Impact factor: 4.132

8.  "In really great danger..." The concept of risk in general practice.

Authors:  S Reventlow; A C Hvas; C Tulinius
Journal:  Scand J Prim Health Care       Date:  2001-06       Impact factor: 2.581

9.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

10.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.